Guardion Health Sciences, Inc. (GHSI)
| Market Cap | 4.35M |
| Revenue (ttm) | 12.23M |
| Net Income (ttm) | 6.37M |
| Shares Out | 1.35M |
| EPS (ttm) | 4.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Sep 24, 2024 |
| Volume | 664 |
| Open | 3.220 |
| Previous Close | 3.290 |
| Day's Range | 3.220 - 3.220 |
| 52-Week Range | 3.040 - 18.000 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About Guardion Health Sciences
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Guardion Health Sciences Announces Filing of Certificate of Dissolution
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Se...
Guardion Health Sciences announces adoption of plan of dissolution and liquidation
Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash dividend in an...
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “...
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, cli...
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution
Guardion Health Sciences Announces
-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Up...
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022
What made Guardion Health stock double on Wednesday?
Guardion Health Sciences Inc (NASDAQ: GHSI) is up nearly 100% this morning after Doctor's Best Inc agreed to buy its Activ Nutritional LLC. Could Guardion Health stock climb any further?
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor's Best Inc.
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell it...
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
Viactiv ® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023
Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstr...
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer
Former President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Business Opportunities Former President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Busines...
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023
Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022 Viactiv® Product Line Total Revenue Increased appro...
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022
Viactiv® Product Line Generated Net Revenues of approximately $10.6 Million or 96% of Net Revenues for the Year Ended December 31, 2022 Viactiv® Product Line Generated Net Revenues of approximately $1...
Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements
HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC...
Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023
HOUSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it will effect a 1-for-50 reverse split of its common stock ...
Guardion Health Sciences Announces Pricing of Aggregate $4.75 Million Institutional Private Placement of Series C and Series D Redeemable Preferred Stock
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a clinical nutrition company that offers a portfolio of science-based, clinicall...
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2022
Viactiv® Generated Net Revenues of Approximately $2.6 Million or 96% of Net Revenues for the Quarter Ended September 30, 2022
Guardion Health Sciences Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks
New Viactiv Omega Boost™ Gel Bites Clinically Proven to Increase Omega-3 Levels by 51% in Just 4 Weeks
Guardion Health Sciences Announces Financial Results for the Quarter Ended June 30, 2022
Viactiv® Product Line Contributes to Highest Quarterly Revenue in Company History of Approximately $3.275 Million, Shows Significant Revenue Growth from Prior Quarter Viactiv® Product Line Contributes...
ISS Recommends Guardion Stockholders Vote for the Increase in Shares for Equity Plan and for the Reverse Stock Split at Guardion's Upcoming 2022 Annual Stockholders' Meeting
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) announced that independent proxy advisory firm ISS recommends that Guardion stock...
Guardion Health Sciences Announces Agreement with OmegaQuant Laboratories
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced an agreement with OmegaQuant Laboratories (“OmegaQuant”) to provide Gua...
Guardion Health Sciences Announces New Viactiv Omega Boost Gel Bites Now Available for Purchase on Amazon
Consumers May Now Purchase Viactiv Omega Boost 1,200 mg Omega-3 Gel Bites Directly from Amazon
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2022
Viactiv® Generated Net Revenues of approximately $2.3 Million or 95% of Net Revenues for the Quarter Ended March 31, 2022 Viactiv® Generated Net Revenues of approximately $2.3 Million or 95% of Net Re...